// App-Quantinova.ai

DOP022 : Vedolizumab and anti-TNFα treatment effectiveness in patients with IBD treated in Germany: a retrospective chart review

Researchers

Presenter

  • R. Ehehalt

Principal Investigators

  • S. Schubert

  • D. Stein

  • D. Lambrelli

  • M. Bassel

  • H.-D. Orzechowski

  • K. Minda

  • J.M. Khalid

Medical Centers

  • Gastroenterology Outpatients Clinic, Leipzig, Germany

  • Gastroenterologist in private practice, Stuhr, Germany

  • Evidera, Montreal, QC, Canada

  • Evidera, Hammersmith, United Kingdom

  • UBC: An Express Scripts Company, Montreal, Canada

  • Takeda Pharma GmbH, Berlin, Germany

  • Takeda Pharmaceutical International AG, Zürich, Switzerland

  • Takeda Development Centre London United Kingdom

Locations

  • Germany

  • Canada

  • United Kingdom

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Entyvio

  • Adalimumab

  • Infliximab

  • golimumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved